Several selective estrogen receptor degraders (SERDs) are progressing into mid-stage development as potential options for human epidermal growth factor receptor 2 (HER2)-negative, hormone receptor (HR)-positive breast cancer. Early clinical data for several of the next generation hormonal therapies were presented at the American Society of Clinical Oncology virtual meeting 29-31 May, including drugs from Sanofi, AstraZeneca PLC and Roche.
The maturing data put a renewed spotlight on the class of drugs. Another drug maker, Zentalis Pharmaceuticals, which had an initial public offering in April after an all virtual roadshow, has a lead drug that is a SERD in development, but did not report data at ASCO. Zentalis' ZN-c5 is in Phase I/II testing with data expected in the second half of 2020. (Also see "Post-IPO Zentalis Plows New Ground With China Oncology Venture" - Scrip, 21 May, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?